Among these subtypes, hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) BC are the most common, accounting for 60–65% of patients with metastatic or advanced BC [3, 6, 7]. Here, ERBB2 is linked to breast cancer.